Mortality and causes of death in inherited antithrombin deficiency by Rosendaal, F.R.
Thrombosis and Haemostasis © F K Schattauer Verlagbgesellschaft mbH (Stuttgart) 77 (3) 452-5 (1997)
Mortality and Causes of Death
in Inherited Antithrombin Deficiency
H, H. van Boven1, J, P. Vandenbroucke1, R. G. J, Westendorp1, F. R. RosendaaP 2
From the ]Department of Clinical Epidemiology, University Hospital Leiden, and
2Hemostasis and Thrombosis Research Center, University Hospital Leiden, The Netherlands
Summary
To assess the contnbution of mhented antithrombin deticiency to
mortdhty, we mvestigated the causes of death in 14 famtlies wtth inher-
tted antithrombm deficiency Between 1830 and 1994, 86 of 266 fami
ly members who had a probabthty of 0 5 or more for heterozygosity
died The causes of death were obtained for 58 ot 66 deaths occumng
between 1940 and 1994 Standardtzed moitahty ratios (SMR) were
calculated ustng mortahty rates from the general populatton adjusted
for age, sex and calendar peitod
The overall SMR was 0 90 from 1830 to 1994 (95% C I 0 72-1 11)
Ftom 1940 tinttl 1994 44 men and 22 women died (SMR = l 09, 95%
C I 0 84-1 39, SMR men = l 20, 95% CI 0 87 l 61, SMR women =
0 92, 95% CI 0 58-1 39) No excess mortahty compared to the gener-
al population was found for cancer (14 deaths) or circulatory diseases
(28 deaths) A shghtly mcieased mortahty caused by respnatory diseas-
es (7 deaths, SMR = l 68,95% CI 0 68-3 47) seemed due to pneumo-
ma (4 deaths, SMR = 2 86, 95% CI 0 78 7 32) Venous thromboem-
bohc complications were hsted once m association with a nsk Situation,
and one other death could be attnbuted to fatal pulmonary embohsm
Ceiebial hemorrhages were hsted three times It could not be venfied
whethei these hemorrhages were lelated to anticoagulant theiapy, the
fiequency was shghtly higher than the expected population figure
(SMR = l 49,95% C I 0 31-4 36) The raean age of death for all caus-
es was 64 years, the two fatal thromboembohc episodes occuned at age
20 and 30 years
The data show that antithrombin deficiency is associated with a
normal survival and a low nsk of fatal thromboembohc events The use
ot long-teim anticoagulant treatment m asymptomatic mdividuals
should be considered caretully in view ot the greater nsk of fatal bleed-
mg associated with long-term anticoagulant prophylaxis
Introduction
Inherited antithrombin deficiency is an uncommon autosomal disor-
dei associated with a tendency to venous thromboembolism In famihes
with mhented antithiombm deficiency, (recurrent) thromboembohc
episodes manifest in heterozygous members, with the tirst thiombosts
usually occurrmg between 20-40 years of age (l) These episodes most-
ly consist of venous thrombosis of the lower extremities and pulmonary
embohsm, though sometimes thrombosis occurs at unusual Sites such
äs cerebral and mesentenc vems These latter mamfestations äs well äs
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pulmonary embohsm can become hfe-threatenmg events and have been
reported äs fatal thiomboembohc complications in some famihes (2)
We have already reported a study of overall mortahty m 10 famihes
with mhented antithrombm deficiency (3) It was found that mhented
antithrombin deficiency did not appear to affect survival äs compared
with the general population Similarly, we found a normal hfe expec-
tancy m famihes with another mhented nsk factor for thrombosis, i e
protem C deficiency (4) Thus. although these genetic disorders m-
ciease the nsk of thrombosis, it was concluded that they do not mcrease
overall mortahty
Although antithrombm deticiency may not lead to a noticeable num-
ber of excess deaths, it may still mcrease specific mortahty ansing from
one or more causes It is conceivable that the overall mortahty figures
mask an mcreased number of deaths due to venous thrombosis We
have therefore in the present study analyzed the causes of death in
14 Dutch famihes with mhented antithrombm deficiency with particu-
lar emphasis on causes related to thrombosis We compared the pattern
of mortahty to that expected in the general population in order to assess
to what extent mhented antithrombm deficiency contnbutes to mortal-
ity
The use of oral anticoagulation will prevent many thrombotic
events, nonfatal and fatal Current guidelmes for mdividuals with anti-
thrombin deficiency are not uniform, especially with regard to long-
term anticoagulant prophylaxis m asymptomatic mdividuals This issue
is important, smce long-term anticoagulant treatment is also associated
with a nsk of disabihty and death from cerebral hemorrhages and other
major hemorrhages (5,6) So, there may even be an excess of deaths of
venous thromboembohc diseases in antithrombm deficiency that is not
outweighed by the nsk of anticoagulant prophylaxis
Methods
Famdies Fourteen Dutch famihes with mhented antithrombm deficiency
participated m this study The diagnosis was mitially based on antithrombin ac-
tivity levels of less than 80% of normal, but smce then many underlymg genet-
ic defects have been identified (7) In 2 famihes a hepann bmdmg defect was
found and m 9, a defect underlymg type I antithrombm deficiency In 3 famihes
with type I deficiency phenotype, a defect has not yet been identified
We used municipal population records and state archives to complete the
pedigrees and to obtam Information on date of birth, date of death and the death
certificates We restnüed our study population to those who were deficient
with certamty and those who had a Mendehan probability of 0 5 of camership
of the defect These genetic probabihties greater than or equal to 0 5 could be
assigned m the pedigrees followmg Mendehan rules smce antithrombm defi-
ciency is a dominant autosomal disorder with a low rate of new mutations All
first degree family members of camers were assigned a probability of 0 5, re-
gardless of the lest results This was done to avoid bias by excludmg mdwidu-
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als who had died prematurely and therefore could not be tested. Hence, we
included complete sibships in the analysis. We used the lest results to include
new generations with 0.5 probability. Follow-up extended frora the date of birth
to December 31,1994 or the date of death.
The causes of death could be obtained for the period 1940 to 1994. On the
death certificates multiple causes are included, coded by specialized physicians
of the Netherlands Central Bureau of Statistics using the International Clas-
sification of Diseases, Injuries and Causes of Death, Fifth to Ninth Revision (8,
10-13). For each death, an underlying ('primary') cause of death and any other
contributing ('secondary') causes to a maximum of three are assigned (9).
We divided the causes into 7 categories: malignant neoplasms (ICD-9 codes
1400-2089), circulatory diseases (ICD-9 codes 3900-4599), cerebrovascular
diseases (ICD-9 codes 4300-4389), ischemic heart diseases (ICD-9 codes
4100-4149), respiratory diseases (ICD-9 codes 4600-5199), pneumonia (ICD-9
codes 4600-4680), and thromboembolic complications. We included in the
thromboembolic category the codes for "pulmonary embolism" (ICD-9 code
4151), "phlebitis and thrombophlebitis" (ICD-9 codes 4510-4519), "other
venous embolism or thrombosis" (ICD-9 codes 4530-4539), "venous complica-
tions in pregnancy and puerperium" (ICD-9 codes 6710-6719), and "obstetrical
pulmonary embolism" (ICD-9 codes 6730-6739) äs they are the most common
venous thromboembolic complications in the general population. We assigned
the ICD-codes and recoded the older ICD-codes following the Ninth Revision
(8,10-13).
For the primary causes of death we obtained from the Netherlands Central
Bureau of Statistics the mortality rates or annual total number of deaths from
which the rates could be computed for 1940 to 1994. Population mortality rates
for secondary causes have been recorded by The Netherlands Central Bureau of
Statistics from 1950 onwards.
Analysis. We calculated standardized mortality ratios (SMRs) äs the ratio of
the number of observed deaths in our study population to the expected number
of deaths in the general population, i.e. the number of deaths that would have
occurred according to the mortality rates of the general population adjusted for
age, sex and calendar period. SMRs were calculated for overall mortality
between 1830 and 1994; cause-specific SMRs from 1940 for underlying disor-
ders and from 1950 for contributing disorders using the Computer program
'Person-Years' (14). The calendar periods were divided into 20-year intervals
for 1830 to 1900, ten-year intervals for 1900 to 1940 and five-year intervals for
1940 to 1994. To calculate the expected number of deaths for each of these
periods, we used the population mortality rates of the mid-interval year subcat-
egorized into five year age groups and by sex.
In 2 families it could not be determined who had been the original probands
and so we counted 12 probands. To eliminate bias that may have led to a false-
ly low SMR, we omitted person-years of the following subjects in our study
cohort: probands were included only from the date of diagnosis; individuals,
whose lest results were used to extend a pedigree, entered the study at the date
of birth of their first child. The rationale is that, in retrospect, probands could
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Fig. l Mortality rates in families with inherited antithrombin deficiency by
calendar period from 1890 to 1994 (äs the year of death ranged from 1890
onwards)
not have died before the date of diagnosis, and persons who transmitted the
gene could not have died before the age of procreation. All other individuals
entered the study at the date of birth. Given the uncertainty about mortality data
for children <1 year old. we omitted the first year of life of the subjects of our
study cohort both for observed and expected deaths. Confidence intervals were
calculated based on a Poisson distribution for the observed number of deaths
(15).
Results
In 14 families, followed from 1830 to 1940,266 individuals were in-
vestigated. From their dates of entry 146 men and 120 women lived a
total of 11210 person-years (all ages combined). The smallest family
contributed 5 individuals to the study group and the largest, 53. In
the families the number of generations varied between 2 and 6. Two
families with antithrombin deficiency type II c were included, together
comprising 12 individuals. A total of 11 subjects emigrated during
follow-up and were censored at the emigration date.
During follow-up 86 individuals died, whereas a total of 95.9 deaths
would have been expected in a hypothetical cohort of the general pop-
ulation with the same sex and age distribution (SMR = 0.90, 95% C.I.
0.72-1.11). Thus, from 1830 to 1994 overall mortality was not in-
creased. The SMR for men was 0.96 (58 deaths, 95% C.I. 0.73-1.25)
and for women 0.79 (28 deaths, 95% C.I. 0.53-1.15). Figure l shows
the mortality rates for the various calendar periods from 1890 onwards.
From 1940 to 1994 all-cause SMR was 1.09 with no differences
between men and women (44 deaths in men, SMR = 1.20; 95% C.I.
0.87-1.61; 22 deaths in women, SMR = 0.92; 95% C.I. 0.58-1.39). For
this period the most frequent causes of death are listed for 58 individu-
als in Table l. The underlying cause of death could not be retrieved
from death certificates in 8 cases: 2 subjects died in World War II;
2 died abroad and for 4 individuals we could not get hold of death
certificates from the municipal records.
Table I Observed number of deaths, and SMR for different causes between
1940 and 1994
Cause of death Number of deaths SMR 95% C.I.
Observed
All causes
men
women
58
39
19
1.00 0.76-
1 1 1 079-
0.84 0.51 -
1 30
1 51
1 32
Neoplasms
Malignant neoplasms
Circulatory diseases
All"
Cerebrovascular diseases
Ischemic heart disease
Thrombo-embohc diseases
Respiratory diseases
All'
Pneumonia
14
28
5
13
1
7
4
0.90
1.18
0.87
1.12
3.23
1.68
286
0.49- 1 51
0.79- 1.71
0.28 - 2.03
0.60- 1.92
0.08-18.00
068- 3.47
0.78- 7.32
mcluding 9 deaths from olhcr heart discascs ' mcludmg 3 deaths from chrontc respiratory
diseases (SMR--I 09. 95% C l 022-3 18)
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Venous thromboembolism was listed only once äs a primary cause:
pulmonary embolism in puerperiurn in a 30 year old woman. Since we
expected 0.31 deaths for venous thromboembolism äs primary cause,
this led to a SMR of 3.23 (95% C.I. 0.08-18.00).
Most deaths (42%) were classified äs caused by circulatory diseases.
This mortality was similar to that in the general population; analogous-
ly, we found no excess of cancer mortality. Mortality due to respiratory
diseases was slightly higher than expected. This seemed to be due to a
higher mortality of pneumonia than expected. Chronic respiratory dis-
eases were responsible for 3 other deaths in this category.
For overall cerebrovascular diseases we found no excess mortality.
This group consisted of 3 cerebral hemorrhages, occlusion of the cere-
bral arteries due to thrombosis in one patient, and an ill-defined vascu-
lar lesion which could have been either hemorrhagic or thrombotic of
origin in one patient.
Other causes (9 deaths) included diseases of the central nervous
System (3 deaths), digestive system (3 deaths), urogenital system
(l death). Two deaths were classified in the category 'Symptoms, signs
and ill defined conditions'. We obtained Information from the family
that a fatal pulmonary embolism had been the cause of one of these two
deaths, a 20 year old man without a specific acquired risk factor. In
total, therefore, venous thromboembolism contributed to 2 deaths, cere-
bral hemorrhages to 3 deaths and occlusion of cerebral arteries to one or
possibly two deaths.
To investigate whether thrombosis could have contributed to more
deaths without having been listed äs the primary cause, we obtained In-
formation of 32 secondary causes from 1950 onwards. As secondary
cause we expected 1.14 deaths for venous thromboembolism but ob-
served none (Table 2). Circulatory diseases (15 deaths) and respiratory
diseases (6 deaths) were the most frequent secondary causes. Cerebro-
vascular diseases äs secondary cause included 3 cases of cerebral
thrombosis and embolism, l occlusion of precerebral arteries and 2 ill-
defined vascular lesions, which could have been either hemorrhagic or
thrombotic in origin. The primary causes given in these cases were
chronic nephritis (l death), cholecystitis (l death) and ischemic heart
disease (4 deaths).
Table 2 Observed and expected number of deaths from thrombosis-related
causes between 1940 and 1994
Thromboembolic complications Number of deaths
Observed Expected
As primary cause
Pulmonary embolism
Venous thrombosis
and thrombophlebitis
Of the puerperiurn 1
031
0.14
0.10
0.07
As secondary cause
Pulmonary embolism
Venous thrombosis
and thrombophlebitis
Of the puerperiurn
1.14
0.91
0.23
The mean age of death (all causes) was 61 years (ränge 2-88) in men,
69 years (ränge 30-83) in women and altogether 64 years. The one
thromboembolic complication in pregnancy led to the youngest death
among women. In men other causes (digestive system, central nervous
system) led to death at a young age. However, the fatal pulmonary em-
bolism coded äs an "ill defined and unknown" cause of death occurred
in a young man aged 20. The mean age of death from respiratory
diseases was 79 years (ränge 64-88) in men and 64 years in women.
For cerebrovascular diseases it was 73 years (ränge 61-85) in men and
76 years (ränge 75-77) in women. It was 82 years (ränge 80-85) for
those deaths in which cerebral thrombosis contributed to mortality with
circulatory diseases äs primary cause, and 58 years when it contributed
to the other primary causes. For the 3 cerebral hemorrhages it was
70 years (ränge 61-75).
Discussion
Investigation of overall mortality from a follow-up from 1830 to
1994 in 14 families revealed a normal life expectancy for individuals
with >0.5 probability of heterozygosity for inherited antithrombin
deficiency. As this finding is not necessarily in conflict with higher
mortality specifically due to venous thrombosis, we compared the
cause-specific mortality in these families with that of the general popu-
lation. A venous thromboembolic complication was listed only once äs
the primary cause of death and was suspected in another death listed äs
''ill defined".
Although two venous thromboembolic complications is higher than
expected for this cohort, it does not indicate that inherited antithrombin
deficiency in these families is associated with a high rate of mortality
due to thrombotic causes. Even including the total number of primary
and secondary causes expected for venous thromboembolic complica-
tions (1.45 deaths), the two deaths do not immediately raise much
concern. One fatal pulmonary embolism occurred during puerperiurn.
In women venous thrombosis often manifests with pregnancy, puerpe-
riurn or the use of oral contraceptives (16). However, we did not find a
sex difference in overall mortality.
No large studies have investigated mortality and causes of death for
inherited antithrombin deficiency before, and fatal thromboembolic
episodes have been reported in some cases or pedigrees (2). Our results
suggest now that those are rare occurrences, and suggest publication or
detection bias in these previously published case reports or pedigree
studies.
Oral anticoagulant treatment will prevent many thromboses. Long-
term antithrombotic prophylaxis reduces the incidence of recurrent epi-
sodes, and when short-term prophylaxis is recommended in asympto-
matic individuals in high-risk situations, a positive effect on morbidity
is seen (16-17). As for mortality, we may conclude that no further ira-
provement of survival is to be expected from long-term anticoagulation
in asymptomatic individuals. Moreover, since fatalities due to throm-
botic episodes remain rare, prevention of these episodes with long-term
anticoagulation in asymptomatic individuals is not indicated because of
the greater risk of induced fatal bleeding. Previously, we estimated this
risk to be 0.6 per 100 treatment years (6).
In this study the fatal thrombotic complications, although few, were
dramatic since they manifested at a young age. The postpartum death in
a women aged 30 years might have been prevented by a policy of giv-
ing anticoagulation for a short period around and after delivery, which
is now common practice in antithrombin deficiency. The other death,
äs far äs we know, occurred outside of any risk Situation in a man aged
20 years, and therefore might only have been prevented by a policy of
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indiscnmmate long-term prophylaxis of asyraptomatic individuals
When applymg the nsk of fatal bleedmg to the several thousand person-
years, this would have led to a considerable number of hemorrhagic
deaths, far outweighmg the benefits
The general Impression is that artenal disease is not a feature of anti-
thrombm deficiency, with the excepüon of homozygous type IIc defi-
ciency where venous äs well äs artenal thrombosis may occur at a very
young age (18) We found no excess mortahty for ischemic heart dis-
eases Ischemic heart diseases are known clearly to be associated with
stroke We found cerebral thrombosis and embohsm menüoned four
times äs secondary cause with ischemic heart diseases In 2 more sub
jects cerebral thrombosis (hsted äs a secondary cause) had contnbuted
to death, at a shghtly younger age, and the pnmary cause was not
ischemic heart disease One cannot exclude that similar pathogenesis ot
atherosclerosis m the cerebral circulation or embohsm from left ven
tncular thrombus complicatmg myocardial mfarction (undiagnosed)
had existed m these 2 individuals
A shghtly higher mortahty due to respiratory diseases seemed due to
a higher mortality of pneumoma No mfectious orgamsms were men-
tioned in the 4 subjects with fatal pneumoma It cannot completely be
ruled out therefore that the higher mortality m this group could be
explamed by misdiagnosis of one or more underlymg pulmonary embo-
hsms If this was the case, venous thromboembohc comphcations were
somewhat underestimated However, the consequence of such an
underestimate is not severe, äs the mean age of death was 75 years for
these individuals
The pattern of mortahty with regard to common causes did not dif-
fer from that in the general population The companson of causes of
death was based on death certificate classifications This guaranteed a
valid companson äs the classification was the same for the study cohort
and the general population Because we included individuals with >0 5
probabihty of bemg deficient, some individuals may, m reahty, have
had normal antithrombin concentrations These normal individuals will
have diluted any observed effect on mortahty, but they cannot explam
that we did not find any difference in overall and specific mortahty
compared to the general population
In conclusion, we found no excess mortality and no high rate of
death from venous thromboembohc diseases The thrombotic fatahties
that were observed developed at a relatively young age, one m associa-
tion with a well known nsk Situation, but their number did not greatly
exceeded the expected number for these occurrences With a greater
nsk of bleedmg man the nsk of fatal thromboembohc comphcations
long-term anticoagulant treatment cannot be recommended for asymp-
tomatic individuals
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